Severe Clostridium difficile infection in New Zealand associated with an emerging strain, PCR-ribotype 244

New Zealand Medical Journal

Volumn 126, Issue 1380, 2013, Pages 9-14

  de Almeida, Mary N ^a   Heffernan, Helen ^b   Dervan, Anne ^a   Bakker, Sarah ^b   Freeman, Joshua T ^a   Bhally, Hasan ^c   Taylor, Susan L ^d   Riley, Thomas V ^e   Roberts, Sally A ^a  

^a AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

^b INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^c WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

^d Division of Medicine Emergency and Integrated Care   (New Zealand)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; METRONIDAZOLE; MOXIFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CASE CONTROL STUDY; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE SEVERITY; ENDOSCOPY; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; MINIMUM INHIBITORY CONCENTRATION; POLYMERASE CHAIN REACTION; PSEUDOMEMBRANOUS COLITIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; RIBOTYPE 244; RISK FACTOR;

CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COMMUNICABLE DISEASES, EMERGING; FEMALE; HUMANS; MALE; NEW ZEALAND; RETROSPECTIVE STUDIES; RIBOTYPING; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VIRULENCE;

EID: 84882671647     PISSN: 00288446     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Kelly CP, La Mont JT. Clostridium difficile-more difficult than ever. N Engl J Med. 2008;359:1932-40
2. Clements ACA, Magalhaes RJS, Taem AJ, et al. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis. 2010;10:395-404.
3. Roberts S, Heffernan H, Al Anbuky N, et al. Molecular epidemiology and susceptibility profiles of Clostridium difficile in New Zealand, 2009. NZ Med J. 2011;124:45-51
4. Roberts S, Heffernan H, Al Anbuky N, et al. Epidemic strains of Clostridium difficile are present in Auckland, New Zealand. NZ Med J. 2011;124:97-101
5. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245-51.
6. McDonald LC, Coignard B, Dubberke E, et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol. 2007;28:140-5.
7. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15:1067-79
8. Indra A, Huhulescu S, Schneeweis M, et al. Characterization of Clostridium difficile isolates using capillary gel electrophoresis-based PCR ribotyping. J Med Microbiol. 2008;57:1377-82
9. Persson S, Torpdahl M, Olsen KE. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clin Microbiol Infect. 2008;14:1057-64
10. Curry SR, Marsh JW, Muto CA, et al. tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol. 2007;45:215-21
11. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement. CLSI document M100-S21. Wayne PA: Clinical and Laboratory Standards Institute; 2011
12. European Committee on Antimicrobial Susceptibility Testing. (2012). Breakpoint tables for interpretation of MICs and zone diameters. Version 2.0. Available at: http://www.eucast.org/clinical-breakpoints/ Accessed 25 October 2012.
13. Ferguson JK, Cheng AC, Gilbert GL, et al. Clostridium difficile laboratory testing in Australia and New Zealand: national survey results and Australasian Society for Infectious Diseases recommendations for best practice. Pathology. 2011;43:482-7
14. Stabler RA, Dawson LF, Valiente E et al. Macro and micro diversity of Clostridium difficile isolates from diverse sources and geographical locations. PLoS One. 2012;7:e31559. doi:10.1371/journal.pone.0031559
15. Valiente E, Dawson LF, Cairns MD, et al. Emergence of new PCR ribotypes from the hypervirulent Clostridium difficile 027 lineage. J Med Microbiol. 2012;61:49-56.
16. Walk ST, Micic D, Jain R, et al. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis. 2012;55:1661-1668.